CA3215295A1 - Crystalline form of a shp2 inhibitor - Google Patents
Crystalline form of a shp2 inhibitor Download PDFInfo
- Publication number
- CA3215295A1 CA3215295A1 CA3215295A CA3215295A CA3215295A1 CA 3215295 A1 CA3215295 A1 CA 3215295A1 CA 3215295 A CA3215295 A CA 3215295A CA 3215295 A CA3215295 A CA 3215295A CA 3215295 A1 CA3215295 A1 CA 3215295A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- triazin
- indene
- amino
- dihydrospiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169340P | 2021-04-01 | 2021-04-01 | |
| US63/169,340 | 2021-04-01 | ||
| US202263321902P | 2022-03-21 | 2022-03-21 | |
| US63/321,902 | 2022-03-21 | ||
| PCT/IB2022/052982 WO2022208408A1 (en) | 2021-04-01 | 2022-03-30 | Crystalline form of a shp2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3215295A1 true CA3215295A1 (en) | 2022-10-06 |
Family
ID=81327112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3215295A Pending CA3215295A1 (en) | 2021-04-01 | 2022-03-30 | Crystalline form of a shp2 inhibitor |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240190843A1 (enExample) |
| EP (1) | EP4313307A1 (enExample) |
| JP (1) | JP2024513798A (enExample) |
| KR (1) | KR20230165309A (enExample) |
| AU (1) | AU2022252094B2 (enExample) |
| BR (1) | BR112023019479A2 (enExample) |
| CA (1) | CA3215295A1 (enExample) |
| MX (1) | MX2023011664A (enExample) |
| WO (1) | WO2022208408A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| AU2023285116A1 (en) | 2022-06-10 | 2024-12-19 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001039975A (ja) * | 1999-07-26 | 2001-02-13 | Eisai Co Ltd | スルホキシド誘導体の結晶およびその製造法 |
| CZ20031098A3 (cs) * | 2000-10-20 | 2003-08-13 | Eli Lilly And Company | Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu |
| ES2416354T3 (es) * | 2005-06-21 | 2013-07-31 | Ajinomoto Co., Inc. | Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo |
| US10287266B2 (en) * | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| PH12019500056B1 (en) * | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| JP7356414B2 (ja) | 2017-09-07 | 2023-10-04 | レヴォリューション・メディスンズ，インコーポレイテッド | がんを治療するためのｓｈｐ２阻害剤組成物および方法 |
| SG11202002941WA (en) * | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CA3084058A1 (en) * | 2017-12-15 | 2019-06-20 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
| MX2021002880A (es) | 2018-09-14 | 2021-06-04 | Unilever Ip Holdings B V | Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes. |
| IL320682A (en) * | 2019-04-02 | 2025-07-01 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
-
2022
- 2022-03-30 MX MX2023011664A patent/MX2023011664A/es unknown
- 2022-03-30 KR KR1020237037693A patent/KR20230165309A/ko active Pending
- 2022-03-30 WO PCT/IB2022/052982 patent/WO2022208408A1/en not_active Ceased
- 2022-03-30 BR BR112023019479A patent/BR112023019479A2/pt unknown
- 2022-03-30 AU AU2022252094A patent/AU2022252094B2/en active Active
- 2022-03-30 EP EP22715194.1A patent/EP4313307A1/en active Pending
- 2022-03-30 JP JP2023559680A patent/JP2024513798A/ja active Pending
- 2022-03-30 CA CA3215295A patent/CA3215295A1/en active Pending
- 2022-03-30 US US18/553,214 patent/US20240190843A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022252094A1 (en) | 2023-10-12 |
| WO2022208408A1 (en) | 2022-10-06 |
| EP4313307A1 (en) | 2024-02-07 |
| AU2022252094B2 (en) | 2024-10-17 |
| BR112023019479A2 (pt) | 2023-12-05 |
| JP2024513798A (ja) | 2024-03-27 |
| MX2023011664A (es) | 2023-10-11 |
| KR20230165309A (ko) | 2023-12-05 |
| US20240190843A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022252094B2 (en) | Crystalline form of a shp2 inhibitor | |
| EP4025574B1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| EP4055021B1 (en) | Heterocyclic rip1 inhibitory compounds | |
| CA3215293A1 (en) | 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors | |
| WO2023130012A1 (en) | Compounds for mutant kras protein degradation and uses thereof | |
| EP4144732A1 (en) | Benzothiazolyl biaryl compound, and preparation method and use | |
| US20220112204A1 (en) | Substituted dihydropyranopyrimidine compounds as kras inhibitors | |
| US10501466B2 (en) | WDR5 inhibitors and modulators | |
| CN113278012B (zh) | 用作激酶抑制剂的化合物及其应用 | |
| KR102833011B1 (ko) | 푸로[3,4-b]피롤-함유 BTK 억제제 | |
| WO2022002100A1 (zh) | 新型苯并咪唑化合物 | |
| CN117460725A (zh) | Shp2抑制剂的晶型 | |
| CN103370321B (zh) | 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途 | |
| AU2023238523B2 (en) | Crystalline salt form of a shp2 inhibitor | |
| CN115894497A (zh) | 一类咪唑并嘧啶化合物、其制备方法及用途 | |
| HK40101911A (zh) | Shp2抑制剂的晶型 | |
| CN115368362A (zh) | 作为btk抑制剂的喹喔啉酮类衍生物及其应用 | |
| RU2826000C1 (ru) | 3,4-дигидро-2,7-нафтиридин-1,6(2h,7h)-дионы в качестве ингибиторов mek | |
| CN113754659A (zh) | 含螺环的喹唑啉化合物 | |
| RU2851633C1 (ru) | Соединения хиназолина, содержащие спиро-кольцо | |
| RU2857201C2 (ru) | Новое соединение пиразина | |
| AU2019101281A4 (en) | Pyridine-2-carboxylic derivative, and preparation method and use thereof | |
| HK40112682A (zh) | Shp2抑制剂的结晶盐形式 | |
| CN120344507A (zh) | 作为布鲁顿氏酪胺酸激酶抑制剂的新颖嘧啶衍生物 | |
| HK40090213A (en) | Benzothiazolyl biaryl compound, and preparation method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230927 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241016 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241029 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241029 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250131 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTERNAL INVESTIGATION REQUEST Effective date: 20260423 |